ReviewFrontiers in immunology2026
Non-immune regulation of tertiary lymphoid structures in cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLS) are ectopic immune aggregates that form in response to chronic inflammation, and their presence across many solid tumors has been associated with improved survival and enhanced responses to immunotherapy. Although current models primarily characterize TLS through the lens of immune aggregation and organization, their formation also depends on reciprocal interactions with the non-immune tumor microenvironment. Fibroblasts, vasculature, extracellular matrix architecture, and tumor metabolism collectively influence TLS development, suggesting that these structures function as emergent tissue ecosystems rather than as immune aggregates alone. In this review, we summarize current evidence on how cancer-associated fibroblasts and the tumor vasculature regulate immune cell recruitment and organization through context-dependent expression of chemokines, adhesion molecules, structural barriers, and vascular niches, before considering how extracellular matrix remodeling and tumor metabolism further shape TLS neogenesis and maturation. Across these processes, non-immune components exhibit dual functions, promoting TLS formation in some contexts while reinforcing immune exclusion and antagonizing TLS in others. We further discuss current spatial technologies that enable in-depth quantification of TLS structure and maturity and clarify the contribution of non-immune components to TLS biology. Due to this increased appreciation of their biological relevance, we discuss the promise of non-immune components as rational targets for combination strategies to enhance TLS function and immunotherapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.